RxDoctor Payments Data

M Asad Karim, MD

Interventional Cardiology · McKinney, TXNPI 1114979168

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,630 of the $4,225 with a category attached, or 62.2%. 10 manufacturers reported payments, led by Abbott at 46.1% of the total. Reporting peaked in 2022 at $2,114 and has fallen 96.2% since, to $80 in 2024. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.

$4,225in general payments, 2019–2025

Across 82 payments — averaging $51.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • CSL Behring$2K
  • Novartis$325
  • Cardiovascular Systems Inc.$102
  • Novo Nordisk$44
  • Boston Scientific$33
  • plus $71 from 4 others
$2,760,739in research payments, 2019–2025

Across 732 payments — averaging $3771.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$1.4M
  • Eli Lilly$669K
  • Astrazeneca UK Limited$372K
  • CSL Behring$221K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$37K
  • AstraZeneca$36K
  • plus $10K from 2 others

What the payments were for

  • Travel & lodging$2,63062%
  • Food & beverage$1,58137%
  • Education$140%

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,225 in reported general payments places this provider in the 20th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$106,592
Medicare patients
325
Services billed
885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$229,021
JardianceEmpagliflozin197$212,945
XareltoRivaroxaban129$155,774
EntrestoSacubitril/Valsartan66$95,142
FarxigaDapagliflozin Propanediol94$84,585
OzempicSemaglutide54$60,859
Repatha SureclickEvolocumab69$57,735
MounjaroTirzepatide20$20,720
Ranolazine ErRanolazine119$12,392
Rosuvastatin Calcium708$8,910
Metoprolol Succinate465$6,915
ClopidogrelClopidogrel Bisulfate347$3,586
Carvedilol405$3,560
Potassium Chloride201$3,017
Losartan Potassium202$1,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$325$95,14266 claims
AstraZenecaFarxiga$14$84,58594 claims
Novo NordiskOzempic$44$60,85954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →